Affiliation:
1. Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine University of Malaya Kuala Lumpur Malaysia
Abstract
AbstractBackground and AimMultiple clinical trials have been conducted to study the potential benefits of vitamin E for the treatment of metabolic dysfunction‐associated steatotic liver disease (MASLD). Despite available evidence, vitamin E is not widely used. This study aimed to assess the effect of vitamin E on serum markers of liver inflammation, specifically serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, and histology, including resolution of metabolic dysfunction‐associated steatohepatitis (MASH), in adult patients with MASLD.MethodsA systematic literature search on randomized controlled trials published in English was conducted using electronic databases. Standardized mean difference (SMD) and mean difference (MD) were used for continuous outcomes, while risk ratio (RR) was used for dichotomous outcomes, with corresponding 95% confidence interval (CI).ResultsA total of eight studies were included in the qualitative synthesis while seven studies were included in the meta‐analysis. Vitamin E significantly reduced serum ALT and AST levels with SMD of −0.82 (95% CI, −1.13 to −0.51) and −0.68 (95% CI, −0.94 to −0.41), respectively. Vitamin E significantly reduced steatosis, lobular inflammation, and hepatocyte ballooning with a MD of −0.60 (95% CI, −0.83 to −0.37), −0.34 (95% CI, −0.53 to −0.16), −0.32 (95% CI, −0.53 to −0.12), and increased MASH resolution with a RR of 1.9 (95%CI, 1.20 to 3.02). However, vitamin E did not reduce fibrosis, with a MD of −0.23 (95% CI, −0.51 to 0.05).ConclusionVitamin E resulted in significant improvement in serum markers of liver inflammation and histology in patients with MASLD.